Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update

Stock Information for Sigyn Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sigyn Therapeutics Inc.

Izotropic Provides Marketing Update
Izotropic Revises License Agreement with The Regents of the University of California
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Life Sciences Investor Forum Agenda Announced for March 13th
Izotropic to Present at Investor Conference March 13th
FDA Sets Meeting Date with Izotropic

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.